Ligand id: 6884

Name: eculizumab

Immunopharmacology Comments
Included in GtoImmuPdb as it acts on the complement system, at the terminal step involved in membrane attack complex formation. The evidence confirming C5, C5a and the C5a receptor as anti-inflammatory drug targets is reviewed by Horiuchi and Tsukamoto (2016) [2].
Immunopharmacology Disease
Disease X-Refs Comment References
Neuromyelitis optica Disease Ontology: DOID:8869
OMIM: 600308
Orphanet: ORPHA71211
FDA approved drug for NMO patients with anti-AQP4 autoantibodies (granted in June 2019). 3
Myasthenia gravis Disease Ontology: DOID:437
OMIM: 254200
Orphanet: ORPHA589
Approved to treat generalized myasthenia gravis in patients with anti-acetylcholine receptor autoantibodies (granted in 2017 by FDA)